Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Thistle and Reduced Low-Density Lipoprotein Level

Research synthesisModerate evidenceSmall effect4 studies · 3 beneficial · 1 neutral · 0 harmful

Across 4 studies, 3 reported beneficial effects of thistle (silymarin/silibinin) on reducing low-density lipoprotein (LDL) levels, with 3 reaching statistical significance. The predominant effect size was small, as shown in the highest-quality meta-analysis (SMD: -0.25). Effects were observed primarily in clinical populations with metabolic or liver conditions, with median study duration of 168 days (24 weeks) in the one study reporting duration.

  • Studied populations: people with nonalcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Dose and form data were too sparse to determine an effective dose range or form-specific effects.

Generated Jul 20, 2026
Doses used in studies
  • mg/day: 103.2 (median 103.2, IQR 103.2103.2) 1 study
Time to effect
Median: 5.6 months · IQR 5.6 months5.6 months · Range 5.6 months5.6 months — Reported in 1 of 4 studies
Safety in these studies
4 of 4 papers
Back to top